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Abstract
Background: The goal of much care in chronic childhood illness is to improve quality of life
(QOL). However, surveys suggest QOL measures are not routinely included. In addition, there is
little consensus about the quality of many QOL measures.
Objectives: To determine the extent to which quality of life (QOL) measures are used in
paediatric clinical trials and evaluate the quality of measures used.
Design: Systematic literature review.
Review Methods: Included paediatric trials published in English between 1994 and 2003 involving
children and adolescents up to the age of 20 years, and use of a standardised QOL measure. Data
Sources included MEDLINE, CINAHL, EMB Reviews, AMED, BNI, PSYCHINFO, the Cochrane
library, Internet, and reference lists from review articles.
Results: We identified 18 trials including assessment of QOL (4 Asthma, 4 Rhinitis, 2 Dermatitis,
and single studies of Eczema, Cystic fibrosis, Otis media, Amblyopia, Diabetes, Obesity associated
with a brain tumour, Idiopathic short stature, and Congenital agranulocytosis). In three trials,
parents rated their own QOL but not their child's. Fourteen different QOL measures were used
but only two fulfilled our minimal defined criteria for quality.
Conclusions: This review confirms previous reports of limited use of QOL measures in paediatric
clinical trials. Our review provides information about availability and quality of measures which will
be of especial value to trial developers.
Review
Introduction
Chronic disease affects approximately 18% of children
[1]. Although cure is not possible, survival rates have
improved substantially for many conditions (e.g. cancer
[2] and cystic fibrosis [3]). Many diseases require daily
self-management and restrict children's physical and
social activities. Consequently questions are increasingly
raised about the quality of life (QOL) of children with
chronic disease.
Efforts to measure child QOL have proved complex but a
number of generic and disease-specific measures have
been reported [4]. Generic measures are designed to assess
and compare health status in patients with different dis-
eases and may provide valuable information for compar-
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are generally well validated and reliable but are often not
recommended for work involving evaluation of ran-
domised controlled trials (RCTs), as they lack sensitivity
to detect small but clinically significant changes in QOL
over time or due to treatment for specific diseases [5]. Dis-
ease specific measures are more suitable for evaluation of
clinical trials designed to assess a particular treatment.
These measures include items that are likely to be affected
by the specific disease or treatment and are therefore more
responsive to clinically significant changes.
The quality of measures must be evaluated according to
performance characteristics. Guidelines suggest good
measures of QOL are reliable and valid for the group of
patients for whom they are used, include a form for self-
report wherever possible, are brief and developmentally
appropriate, and allow completion by proxy [4].
There is little evidence that QOL measures are routinely
used in clinic practice [6] or clinical trials [7], despite the
fact that the aim in many trials is to improve QOL. In both
child [8] and adult work [9], few trials include measures
of QOL, and amongst those, non-standardised measures
continue to be used. QOL is also frequently insufficiently
analyzed, reported or discussed in the study report or sub-
sequent publications [5], despite the increasing emphasis
in clinical practice and research to use patient centered
outcomes and child perspectives [10].
We report a systematic review drawing on established
methodologies [11] to determine first, the extent to which
QOL measures are used in paediatric clinical trials and




The following databases were searched: MEDLINE 1966
to Nov Week 2 2003, CINAHL 1982 to December Week 1
2003, EMB Reviews: Cochrane Central Register of Con-
trolled Trials, Your Journals at OVID, EMB reviews: ACP
Journal Club 1991 to July / August 2003, EMB reviews:
Database of Abstracts and Reviews of Effects 3rd quarter
1993, AMED (Allied & Contemporary Medicine) 1985 to
December 2003, British Nursing Index (BNI) 1985 –
October 2003, EMBASE, PSYCHINFO 1872–2003.
Text word and thesaurus searches were used to minimise
the chance of missing relevant articles. The following key-
words were searched:
• child, childhood, children, adolescent, infant, pediatric,
paediatric,
• quality of life, QOL,
• clinical trial, randomised controlled trial
Searches were restricted to English language papers.
Search engines were used to search the Internet with key-
words and Boolean logic. Additional references from arti-
cles identified through these searches were also pursued.
Inclusion Criteria
These included:
1) Children and adolescents up to the age of 20 years,
2) RCT, formal cross-over trial, or studies evaluating one
or more active drug treatment with or without placebo,
3) Standardised QOL measure (For these purposes we
drew on a previous review [4] and defined minimal psy-
chometric criteria to include some preliminary reliability
and validity data),
4) Articles published in English between January 1994
and December 2003.
Exclusion Criteria
1) Samples including both adults and children.
2) Comparison of surgical treatment, pain control, pallia-
tive medication, or psychological/homeopathic interven-
tion.
3) Outcomes evaluated in terms of medical data only,
non-standardised measures of QOL or standardised psy-
chological measures including symptom checklists, meas-
ures of self-esteem, or coping.
Procedure
Abstracts were reviewed for relevance and full articles
obtained where appropriate. A summary sheet was devel-
oped and both authors independently reviewed papers to
ensure reliability. Data extracted by reviewers was second
coded and compared and any discrepancies were resolved
through discussion.
Results
Of the 917 records retrieved from the databases, initial
inspection suggested that 27 abstracts met the inclusion
criteria. On reading the full articles, nine failed to meet
inclusion criteria. The resulting 18 articles were included
in the review [12-29].Page 2 of 5
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Additional file 1])
• Disease: QOL was most frequently included in trials in
atopic diseases (Asthma = 4, Rhinitis = 4, Dermatitis = 2
and Eczema = 1). Single studies were identified in Cystic
fibrosis, Otis media, Amblyopia, Diabetes, Obesity associ-
ated with a brain tumour, Idiopathic short stature, and
Congenital agranulocytosis.
• Location: Seven studies were conducted in the U.S.A, 4
in the U.K, 3 in the Netherlands, one in Taiwan, and one
in Israel. Two studies were multi-national.
• Child's age: Three studies recruited children across a
broad age range (1 to 18 years), 2 focused on pre-school
children (1–5 years), 4 on pre-school and middle child-
hood (2–10 years), 2 on middle childhood (6–12 years),
6 on middle childhood and adolescence (5–18 years),
and one on adolescents alone (12–17 years).
• Sample size: Sample size ranged from 19 [29] to 689
[15]. Power calculations were reported in six studies.
• Design and trial aim: We identified 11 RCTs, 2 cross-
over studies, and 5 studies comparing two or more active
treatments without placebo or control group. Of the 11
RCTs, 1 was multi-national, 7 multi centre, and 3 single
centre studies. Of the 7 non RCTs, 1 was multi-national, 2
were multi centre, and 4 single centre. Nine articles
involved comparisons of two or more treatment and the
remainder involved comparison of treatments with pla-
cebo.
• Blinding: Seven RCTs reported blinding procedures.
• Parent and caregiver QOL: Fifteen studies measured the
impact of the disease on the child's QOL. Three included
assessment of the caregivers QOL.
• Respondent for child QOL: Of the 15 studies focusing
on child QOL, 10 were based on child, and 3 on parent
reports. In two studies both children and parents reported
the child's QOL and in one of these clinicians also rated
child QOL [28].
Quality of QOL measures (Table 2 [see Additional file 2])
• Generic or disease specific: In total, 12 disease specific
and two generic measures were used [30-38]. The four
asthma trials involved three different measures of asthma
specific QOL. The four perennial rhinitis trials used two
different measures of rhinitis specific quality of life, and
the two atopic dermatitis trials and one atopic eczema
trial used two different dermatology specific measures of
QOL. In two studies authors had developed their own dis-
ease specific measure [25,29].
• Quality of measure: We assessed quality of measures
based on minimal accepted criteria [4] whereby measures
should be brief, allow proxy and self report and include
reliability and validity data and age appropriate versions.
Although all measures included some preliminary psy-
chometric data, only two measures fulfilled all of these
criteria [36,38]. Three measures fulfilled four criteria but
lacked age appropriate versions. The remaining measures
fulfilled three or less criteria.
Discussion
Despite extensive searches we identified only 18 pub-
lished reports of paediatric trials including standardised
QOL measures. This undoubtedly represents a very small
percentage of paediatric trials and supports previous find-
ings that QOL data is seldom reported in paediatric clini-
cal trials [8]. Asthma and rhinitis were most frequently
studied, perhaps because there is higher incidence for
these conditions in children compared to other condi-
tions such as cancer and cystic fibrosis [39]. Further expla-
nations include the non-life threatening nature of these
conditions as well as the availability of disease specific
measures compared to rarer illnesses.
In considering why there are relatively few trials including
QOL measures, it is important to take into account the
aims and purpose of the trial [40,41]. The aim of most tri-
als is to assess the impact of treatment on clinical varia-
bles, with QOL viewed to be of secondary importance if at
all. It is not necessarily appropriate that QOL measures are
included in all trials. Where QOL assessment is appropri-
ate however, inclusion of a QOL measure must be hypoth-
esis driven and an integral part of the clinical
development programme rather than an added after-
thought [5].
Quality of measures
Where QOL was measured, disease specific measures were
most often used (N = 12) as is normally recommended for
use in clinical trials. Only two trials included measures
that satisfactorily fulfilled accepted criteria [4]. Typically,
information about measures included some reliability
data although a third of studies failed to provide informa-
tion about the validity of the scale. Most measures were
brief and contained less than 30 items but many lacked
age appropriate versions or parallel versions for child and
proxy raters.
Selection of a measure of QOL is dependent on the psy-
chometric properties of the instrument, as well as clinical
and demographic variables characteristic of the sample.
However, psychometric properties depend upon samples
for which the scale has been validated. Hence it is impor-
tant to ensure measures are used with clinical populations
where psychometric data are available.Page 3 of 5
(page number not for citation purposes)
Health and Quality of Life Outcomes 2004, 2:66 http://www.hqlo.com/content/2/1/66There are some grounds for assuming that QOL changes
during childhood, and therefore satisfactory measures tar-
get specific age groups [42]. There are difficulties identify-
ing single measures that are appropriate across a wide age
range and only half of measures identified in this review
included age appropriate versions.
It is also generally recommended that ratings of QOL
should be made by children themselves whenever possi-
ble [43]. In cases of younger children proxy reports are
necessary but there are questions about the relationship
between child and parent report [4]. It is therefore positive
that most (73.3%) studies obtained ratings from children
with only four relying on parents alone to provide proxy
ratings.
CONSORT [44] guidelines recommend methods of
reporting RCTs, but do not adequately deal with the issues
concerning QOL assessment and psychometric validity. It
is essential that trial developers select appropriate meas-
ures and are aware of the problems associated with QOL
assessment.
Barriers to inclusion of QOL measures
Objections to inclusion of QOL measures in trials involve
anticipated increased costs, extra time needed to gain
patient and parent consent, and lack of sophistication of
currently available measures [8]. A major restriction to
inclusion of QOL assessment in clinical trials remains
limitations in currently available measures, especially for
less prevalent chronic conditions. However, it is only
through including measures that we will learn more and
be able to develop a second generation of measures that
do show more sophisticated properties.
A second problem is that disease specific measures may
simply not be available for rare conditions. Attempts to
develop such measures are promising and in this review
instruments for ambylopia [25] and agranulocytosis [29]
had been developed. In order to facilitate collection of
QOL data from children with chronic illness, reliable and
valid measures are increasingly required [46].
Other methodological limitations in current work include
the lack of power calculations. Where the aim of the trial
includes QOL assessment, power calculations must be
performed and are an essential element of clinical trial
design. In cases where measurement of QOL is a second-
ary endpoint, sample size calculations are rare and diffi-
cult to establish. However attempts should be made to
hypothesise expected changes in QOL scores in relation to
the agreed sample size prior to the trial [5].
Conclusion
This review supports previous findings of limited use of
QOL measures in paediatric cancer trials [9] and extends
this to include a number of conditions other than cancer.
QOL assessment is most common in trials where the aim
is to compare the impact of treatment on clinical variables
and is largely limited to common non-life threatening
conditions.
The measurement of QOL provides valuable information
about the psychological and social impact of treatment on
children especially where no differences in survival rates
are anticipated. For this reason, the inclusion of QOL
measurement in paediatric trials is becoming increasingly
valued and mandatory [47,48]. There are still questions
concerning selection of QOL measures and how best to
report findings [49], but our review provides useful infor-
mation for trial developers regarding the availability and
quality of QOL measures.
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